dr. van tilburg on larotrectinib in trk pediatric cancers
Published 5 years ago • 139 plays • Length 0:52Download video MP4
Download video MP3
Similar videos
-
5:21
cornelis van tilburg, asco 2019 - larotrectinib in pediatric trk fusion cancer
-
1:29
dr. demetri on larotrectinib in trk-fusion gi cancers
-
4:36
trk inhibition: personal experience with larotrectinib
-
1:35
dr. drilon on activity of larotrectinib in trk fusion–positive nsclc
-
3:18
larotrectinib in adult and pediatric patients with trk fusion-positive primary cns tumors
-
5:20
trk inhibitor in gi cancers: adverse effect profile
-
7:14
larotrectinib for solid tumors with ntrk gene fusions
-
1:15
larotrectinib, a trk inhibitor for patients with solid tumors
-
3:20
approaching treatment for trk fusion–positive cancers
-
5:08
larotrectinib for ntrk fusions: patient selection
-
4:25
updated data for larotrectinib
-
0:52
the impact of trk inhibitor loxo-101 (larotrectinib) on patients with trk fusion cancers
-
2:49
larotrectinib: the first fda-approved trk inhibitor
-
2:10
how will larotrectinib be used?
-
0:21
copy of dr. drilon discusses the fda approval of larotrectinib
-
2:53
other approaches to trk-fusion cancers
-
0:54
efficacy results for loxo-101 in trk fusion cancers
-
2:40
understanding larotrectinib’s safety profile
-
0:34
challenges in treating trk fusion cancer